Global BioGenerics Market in 2010 - A Consensus Market Models report

BioGenerics is an umbrella term used to define the market for bioequivalent products based on the same biological substance used in off-patent biologics. The BioGeneric market is set to develop slowly in the major pharmaceutical markets, as a result of regulatory hurdles and continued protectionism from patented biopharmaceutical marketers. Once the market does begin to evolve, the biogeneric companies entering the market early will derive significant value.

Using a proprietary methodology, this Consensus Market Model report analyses the potential market for BioGenerics products by the year 2010. The 50 page report will provide you with the necessary insight to make informed decisions about this extremely exciting market.

“Biopharmaceuticals are set to win market share not only in monetary terms but also in numbers of products on the market”

Key findings of this report

> A Consensus Market Model forecast for the global BioGenerics market in 2010 of $2.3 billion

> Current off-patent blockbusters including erythropoietin, represent an excellent opportunity

> Significant obstacles associated with manufacturing and marketing BioGenerics has reduced the number of potential BioGenerics companies to less than ten

> A key market event is the launch of Omnitrop in Australia in late 2005 or early 2006

Why read this report

> Understand key market conditions that underpin the future of BioGeneric products

> Assess the current market research and analysis from a broad range of sources

> Learn how regulatory authorities are shaping the market

> Gain insight into which companies are working in this area

Base your forecast on key market conditions - not potential headline figures

Author S. Seget

Publication date November 2005

Pages 50

Format: PDF

Table of Contents
Price: $950.00 / GBP475.00